Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Neoplasms of the CNS

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 41 articles: HTML format

Single Articles

January 2022
1. SKAYEM C, Garcia G, Grill J, Aghakhani N, et al
   First case of a melanocytic intrabulbar brain tumour treated with bevacizumab.
   Eur J Cancer. 2022;162:206-208.
   PubMed    
   
   
   
2. STEINDL A, Brunner TJ, Heimbach K, Schweighart K, et al
   Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.
   Eur J Cancer. 2022;162:170-181.
   PubMed     Abstract available
   
   
   November 2021
3. VASSELLA E, Kashani E, Zens P, Kundig A, et al
   Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
   Eur J Cancer. 2021;159:227-236.
   PubMed     Abstract available
   
   
   
4. SCHULPEN M, Visser O, Reedijk AMJ, Kremer LCM, et al
   Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s.
   Eur J Cancer. 2021;157:81-93.
   PubMed     Abstract available
   
   
   October 2021
5. KARSCHNIA P, Le Rhun E, Vogelbaum MA, van den Bent M, et al
   The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy.
   Eur J Cancer. 2021;156:93-108.
   PubMed     Abstract available
   
   
   August 2021
6. GKEKAS I, Novotny J, Kaprio T, Beilmann-Lehtonen I, et al
   Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases.
   Eur J Cancer. 2021;157:1-9.
   PubMed     Abstract available
   
   
   
7. HILBERS ML, Dimitriou F, Lau P, Bhave P, et al
   Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
   Eur J Cancer. 2021;156:149-163.
   PubMed     Abstract available
   
   
   
8. LOMBARDI G, Del Bianco P, Brandes AA, Eoli M, et al
   Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
   Eur J Cancer. 2021;155:179-190.
   PubMed     Abstract available
   
   
   July 2021
9. LE DU F, Dieras V, Curigliano G
   The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
   Eur J Cancer. 2021;154:175-189.
   PubMed     Abstract available
   
   
   May 2021
10. CHORTI E, Kebir S, Ahmed MS, Keyvani K, et al
    Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Eur J Cancer. 2021;148:395-404.
    PubMed     Abstract available
    
    
    April 2021
11. VERBRUGGEN LC, Kok JL, Teepen JC, Janssens GO, et al
    Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study.
    Eur J Cancer. 2021;150:240-249.
    PubMed     Abstract available
    
    
    
12. ZHENG MM, Tu HY, Yang JJ, Zhang XC, et al
    Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Eur J Cancer. 2021;150:23-30.
    PubMed     Abstract available
    
    
    
13. DIMITRIOU F, Zaremba A, Allayous C, Kahler KC, et al
    Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Eur J Cancer. 2021;149:37-48.
    PubMed     Abstract available
    
    
    
14. KARSCHNIA P, Vogelbaum MA, van den Bent M, Cahill DP, et al
    Evidence-based recommendations on categories for extent of resection in diffuse glioma.
    Eur J Cancer. 2021;149:23-33.
    PubMed     Abstract available
    
    
    March 2021
15. PARTANEN M, Anghelescu DL, Hall L, Schreiber JE, et al
    Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma.
    Eur J Cancer. 2021;148:103-111.
    PubMed     Abstract available
    
    
    February 2021
16. GRAMATZKI D, Felsberg J, Hentschel B, Wolter M, et al
    Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Eur J Cancer. 2021;147:84-94.
    PubMed     Abstract available
    
    
    
17. CLEMENT PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, et al
    Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Eur J Cancer. 2021;147:1-12.
    PubMed     Abstract available
    
    
    
18. BERLANGA P, Pasqualini C, Potschger U, Sanguesa C, et al
    Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Eur J Cancer. 2021;144:1-8.
    PubMed     Abstract available
    
    
    January 2021
19. TOSONI A, Gatto L, Franceschi E, Di Nunno V, et al
    Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
    Eur J Cancer. 2021;145:171-178.
    PubMed     Abstract available
    
    
    December 2020
20. CARAMANNA I, Bottomley A, Drijver AJ, Twisk J, et al
    Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Eur J Cancer. 2020;144:162-168.
    PubMed     Abstract available
    
    
    November 2020
21. HONG AM, Waldstein C, Shivalingam B, Carlino MS, et al
    Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
    Eur J Cancer. 2020;142:10-17.
    PubMed     Abstract available
    
    
    October 2020
22. RAUSCHENBACH L, Wieland A, Reinartz R, Kebir S, et al
    Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
    Eur J Cancer. 2020;140:130-139.
    PubMed     Abstract available
    
    
    September 2020
23. MORENO L, Barone G, DuBois SG, Molenaar J, et al
    Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Eur J Cancer. 2020;136:52-68.
    PubMed     Abstract available
    
    
    July 2020
24. FRANCESCHI E, Tosoni A, Bartolini S, Minichillo S, et al
    Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas.
    Eur J Cancer. 2020;137:10-17.
    PubMed     Abstract available
    
    
    
25. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    PubMed     Abstract available
    
    
    June 2020
26. BERGHOFF AS, Wippel C, Starzer AM, Ballarini N, et al
    Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer.
    Eur J Cancer. 2020;135:150-158.
    PubMed     Abstract available
    
    
    
27. CARRON R, Gaudy-Marqueste C, Amatore F, Padovani L, et al
    Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy.
    Eur J Cancer. 2020;135:52-61.
    PubMed     Abstract available
    
    
    May 2020
28. WOLPERT F, Berghoff AS, Grossenbacher B, Lareida A, et al
    Venous thromboembolic events in patients with brain metastases: the PICOS score.
    Eur J Cancer. 2020;134:75-85.
    PubMed     Abstract available
    
    
    
29. PAGE S, Milner-Watts C, Perna M, Janzic U, et al
    Systemic treatment of brain metastases in non-small cell lung cancer.
    Eur J Cancer. 2020;132:187-198.
    PubMed     Abstract available
    
    
    April 2020
30. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    PubMed     Abstract available
    
    
    March 2020
31. CREED JH, Smith-Warner SA, Gerke TA, Egan KM, et al
    A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank.
    Eur J Cancer. 2020;129:123-131.
    PubMed     Abstract available
    
    
    
32. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Abstract available
    
    
    January 2020
33. ACKER G, Zollfrank J, Jelgersma C, Nieminen-Kelha M, et al
    The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
    Eur J Cancer. 2020;126:106-115.
    PubMed     Abstract available
    
    
    December 2019
34. PASQUIER D, Darlix A, Louvel G, Fraisse J, et al
    Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Eur J Cancer. 2019;125:22-30.
    PubMed     Abstract available
    
    
    October 2019
35. GROSSI F, Genova C, Crino L, Delmonte A, et al
    Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Eur J Cancer. 2019;123:72-80.
    PubMed     Abstract available
    
    
    
36. HENDRIKS LEL, Dooms C, Berghmans T, Novello S, et al
    Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.
    Eur J Cancer. 2019;123:28-35.
    PubMed     Abstract available
    
    
    September 2019
37. JIANG T, Zhang Y, Li X, Zhao C, et al
    EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Eur J Cancer. 2019;121:98-108.
    PubMed     Abstract available
    
    
    
38. LLUCH A, Gonzalez-Angulo AM, Casadevall D, Eterovic AK, et al
    Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
    Eur J Cancer. 2019;120:54-64.
    PubMed     Abstract available
    
    
    August 2019
39. CHANG LC, Lim CK, Chang LY, Chen KY, et al
    Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Eur J Cancer. 2019;119:77-86.
    PubMed     Abstract available
    
    
    June 2019
40. HENDRIKS LEL, Bootsma G, Mourlanette J, Henon C, et al
    Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Eur J Cancer. 2019;116:182-189.
    PubMed     Abstract available
    
    
    January 2019
41. MONTEMURRO F, Ellis P, Anton A, Wuerstlein R, et al
    Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Eur J Cancer. 2019;109:92-102.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: